チクングニアの世界市場レポート 2025年

チクングニア市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.4％で9億3,000万米ドルに成長します。予測期間中の成長は、臨床試験の世界の増加、高齢者人口の増加、予防接種需要の高まり、政府および非政府機関のイニシアティブの拡大、政府投資の増加、有利な政策などの要因に起因すると考えられます。この期間の主な動向としては、ワクチン開発のためのバイオテクノロジーの発展、ワクチン研究における新たな機会、革新的なソリューションのためのCRISPRやAIの利用、製薬企業間の戦略的提携、遠隔医療サービスの統合などが挙げられます。

蚊が媒介する疾病の流行の増加は、今後数年間のチクングニア市場の成長を促進すると予想されます。チクングニア、デング熱、ジカウイルスなどの蚊媒介性疾患は、感染したイエネコを介してヒトに感染し、世界的に公衆衛生上の重大な課題となっています。これらの疾病の発生率の増加は、気候変動、都市化、森林伐採、滞留水の蓄積、不十分な媒介蚊対策、世界の旅行の増加、殺虫剤耐性などの要因に影響されています。チクングニア治療は、発熱、関節痛、炎症などの症状を緩和し、全体的な快適さと可動性を向上させ、合併症を減らし、水分補給、疼痛管理、支持療法を通じて回復を促進することで、患者を助ける。例えば、2024年12月、英国健康安全保障局は、2024年1月から6月にかけて、イングランド、ウェールズ、北アイルランドにおける帰国旅行者のデング熱患者数が473人に急増し、2023年の同時期に報告された157人と比べて201％増加したと報告しました。このような蚊が媒介する疾患の世界の発生率の増加が、チクングニア市場の成長に拍車をかけています。

チクングニア市場の主要企業は、免疫力を高め、疾病の発生を予防し、チクングニアウイルス感染による世界の健康負担の増大に対処するため、革新的ワクチンの開発に注力しています。そのような技術革新のひとつが弱毒化生ワクチンで、弱毒化したウイルスを使用することにより、病気を引き起こすことなく免疫反応を刺激し、長期的な防御を提供します。例えば、2023年11月、フランスに本社を置くバイオテクノロジー企業であるValneva SE社は、弱毒化した生チクングニアワクチンであるIXCHIQが米国食品医薬品局（FDA）から承認されたことを発表しました。この承認は、抗CHIKV中和抗体価に基づく迅速承認に基づいており、承認継続にはさらなる試験での臨床的有用性の確認が条件となります。また、バルネバはFDAから優先審査バウチャー（PRV）を受領しており、このPRVを活用して研究開発を支援する予定です。IXCHIQは単回注射で投与され、チクングニアウイルスの弱毒化した生ウイルスが含まれているため、本疾患に類似した軽度の症状を引き起こす可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界チクングニア PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のチクングニア市場：成長率分析
• 世界のチクングニア市場の実績：規模と成長, 2019-2024
• 世界のチクングニア市場の予測：規模と成長, 2024-2029, 2034F
• 世界チクングニア総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のチクングニア市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ウイルス薬
• ハーブ療法と補完療法
• 支持療法
• ワクチン
• 世界のチクングニア市場：製品形態別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 液体
• 粉
• ソリッドフォーム
• 世界のチクングニア市場病気のステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性
• 慢性
• 感染後
• 世界のチクングニア市場：販売チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• スーパーマーケット
• 世界のチクングニア市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 介護者
• ヘルスケア従事者
• 患者
• 世界のチクングニア市場抗ウイルス薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヌクレオシド類似体
• プロテアーゼ阻害剤
• 世界のチクングニア市場ハーブ療法と補完療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アーユルヴェーダ療法
• ホメオパシー治療
• 伝統中国医学
• 世界のチクングニア市場支持療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鎮痛剤（NSAIDs、アセトアミノフェン）
• 輸液療法
• 理学療法
• 世界のチクングニア市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化ワクチン
• 不活化ワクチン
• mRNAベースのワクチン

第7章 地域別・国別分析

• 世界のチクングニア市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のチクングニア市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• チクングニア市場：競合情勢
• チクングニア市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eurofins Scientific SE
• Grifols Diagnostic Solutions Inc.
• bioMerieux SA
• Bio-Rad Laboratories Inc.
• DiaSorin S.p.A.
• Euroimmun AG
• Evotec SE
• Valneva SE
• ELITechGroup S.A.S.
• Vaxart Inc.
• BioPerfectus Biotechnology Co. Ltd.
• CTK Biotech Inc.
• Creative Diagnostics Inc.
• Inovio Pharmaceuticals Inc.
• Biotrol Laboratories Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• チクングニア市場2029：新たな機会を提供する国
• チクングニア市場2029：新たな機会を提供するセグメント
• チクングニア市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chikungunya (CHIKV) is a viral infection caused by the chikungunya virus, primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. The infection causes symptoms such as fever, joint pain, headache, rash, and muscle pain, which significantly affect the quality of life of those who are infected.

The main product types for chikungunya include antiviral drugs, herbal and complementary treatments, supportive care, and vaccines. Antiviral drugs are designed to prevent or treat viral infections by inhibiting the replication of viruses in the body. These medications come in various forms, such as liquids, powders, and solids, and are used at different stages of the disease, including acute, chronic, and post-infection stages. These products are distributed through a variety of sales channels, including hospital pharmacies, online pharmacies, retail pharmacies, and supermarkets, and are used by various end users such as caregivers, healthcare professionals, and patients.

The chikungunya market research report is one of a series of new reports from The Business Research Company that provides chikungunya market statistics, including the chikungunya industry global market size, regional shares, competitors with the chikungunya market share, detailed chikungunya market segments, market trends, and opportunities, and any further data you may need to thrive in the chikungunya industry. This chikungunya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chikungunya market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.65 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period can be attributed to factors such as rising per capita healthcare expenditures, the growing prevalence of emerging and re-emerging infectious diseases, increased personal disposable income, climate change, and heightened awareness of mosquito-borne diseases.

The chikungunya market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth during the forecast period can be attributed to factors such as a global increase in clinical trials, a growing geriatric population, a rising demand for immunization, expanding government and non-government initiatives, increased government investments, and favorable policies. Key trends during this period include advancements in biotechnology for vaccine development, new opportunities in vaccine research, the use of CRISPR and AI for innovative solutions, strategic collaborations among pharmaceutical companies, and the integration of telemedicine services.

The increasing prevalence of mosquito-borne diseases is expected to drive the growth of the chikungunya market in the coming years. Mosquito-borne diseases, including chikungunya, dengue, and the Zika virus, are transmitted to humans through infected Aedes mosquitoes and present significant global public health challenges. The rising incidence of these diseases is influenced by factors such as climate change, urbanization, deforestation, stagnant water accumulation, insufficient vector control measures, increased global travel, and insecticide resistance. Chikungunya treatment helps patients by alleviating symptoms such as fever, joint pain, and inflammation, improving overall comfort and mobility, reducing complications, and promoting recovery through hydration, pain management, and supportive care. For instance, in December 2024, the UK Health Security Agency reported that between January and June 2024, the number of dengue cases among returning travelers in England, Wales, and Northern Ireland surged to 473, a 201% increase compared to the 157 cases reported during the same period in 2023. This growing global incidence of mosquito-borne diseases is fueling the growth of the chikungunya market.

Leading companies in the chikungunya market are focusing on the development of innovative vaccines to enhance immunity, prevent disease outbreaks, and address the rising global health burden of chikungunya virus infections. One such innovation is the live attenuated chikungunya vaccine, which uses a weakened form of the virus to stimulate an immune response without causing the disease, providing long-term protection. For example, in November 2023, Valneva SE, a France-based biotechnology company, announced the approval of IXCHIQ, a live attenuated chikungunya vaccine, by the U.S. Food and Drug Administration (FDA). This approval was granted under accelerated approval based on anti-CHIKV neutralizing antibody titers, with continued approval contingent on confirming clinical benefits in further studies. Valneva also received a Priority Review Voucher (PRV) from the FDA, which it plans to monetize to support its research and development efforts. IXCHIQ is administered as a single-dose injection and contains a live, weakened form of the chikungunya virus, which may cause mild symptoms similar to the disease.

In February 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired the travel vaccine portfolio from Emergent BioSolutions Inc. for USD 380 million. This acquisition aims to strengthen Bavarian Nordic's position in the travel vaccine market by adding marketed vaccines such as Vivotif for typhoid fever prevention, Vaxchora for cholera prevention, and a phase 3 vaccine candidate for chikungunya virus prevention. Emergent BioSolutions Inc., a US-based life sciences company, also offers chikungunya vaccines.

Major players in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.

North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chikungunya report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chikungunya market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chikungunya market consists of revenues earned by entities by providing services such as vaccination services, diagnostic testing services, and consultation and medical care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chikungunya market also includes sales of vaccines, diagnostic kits, supportive therapies, and diagnostic equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chikungunya Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chikungunya market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chikungunya ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chikungunya market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Antiviral Drugs; Herbal And Complementary Treatments; Supportive Care; Vaccines
• 2) By Product Form: Liquid Form; Powder; Solid Form
• 3) By Disease Stage: Acute; Chronic; Post-Infection
• 4) By Sales Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Supermarkets
• 5) By End User: Caregivers; Healthcare Professionals; Patients
• Subsegments:
• 1) By Antiviral Drugs: Nucleoside Analogues; Protease Inhibitors
• 2) By Herbal And Complementary Treatments: Ayurvedic Remedies; Homeopathic Treatments; Traditional Chinese Medicine
• 3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen); Fluid Therapy; Physiotherapy
• 4) By Vaccines: Live-Attenuated Vaccines; Inactivated Vaccines; mRNA-Based Vaccines
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Thermo Fisher Scientific Inc.; Takeda Pharmaceutical Company Limited; Quest Diagnostics Incorporated
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chikungunya Market Characteristics

3. Chikungunya Market Trends And Strategies

4. Chikungunya Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chikungunya Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chikungunya PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chikungunya Market Growth Rate Analysis
• 5.4. Global Chikungunya Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chikungunya Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chikungunya Total Addressable Market (TAM)

6. Chikungunya Market Segmentation

• 6.1. Global Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Drugs
• Herbal And Complementary Treatments
• Supportive Care
• Vaccines
• 6.2. Global Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Form
• Powder
• Solid Form
• 6.3. Global Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute
• Chronic
• Post-Infection
• 6.4. Global Chikungunya Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Supermarkets
• 6.5. Global Chikungunya Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Caregivers
• Healthcare Professionals
• Patients
• 6.6. Global Chikungunya Market, Sub-Segmentation Of Antiviral Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside Analogues
• Protease Inhibitors
• 6.7. Global Chikungunya Market, Sub-Segmentation Of Herbal And Complementary Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ayurvedic Remedies
• Homeopathic Treatments
• Traditional Chinese Medicine
• 6.8. Global Chikungunya Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain Relievers (NSAIDs, Acetaminophen)
• Fluid Therapy
• Physiotherapy
• 6.9. Global Chikungunya Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live-Attenuated Vaccines
• Inactivated Vaccines
• mRNA-Based Vaccines

7. Chikungunya Market Regional And Country Analysis

• 7.1. Global Chikungunya Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chikungunya Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chikungunya Market

• 8.1. Asia-Pacific Chikungunya Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chikungunya Market

• 9.1. China Chikungunya Market Overview
• 9.2. China Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chikungunya Market

• 10.1. India Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chikungunya Market

• 11.1. Japan Chikungunya Market Overview
• 11.2. Japan Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chikungunya Market

• 12.1. Australia Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chikungunya Market

• 13.1. Indonesia Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chikungunya Market

• 14.1. South Korea Chikungunya Market Overview
• 14.2. South Korea Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chikungunya Market

• 15.1. Western Europe Chikungunya Market Overview
• 15.2. Western Europe Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chikungunya Market

• 16.1. UK Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chikungunya Market

• 17.1. Germany Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chikungunya Market

• 18.1. France Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chikungunya Market

• 19.1. Italy Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chikungunya Market

• 20.1. Spain Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chikungunya Market

• 21.1. Eastern Europe Chikungunya Market Overview
• 21.2. Eastern Europe Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chikungunya Market

• 22.1. Russia Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chikungunya Market

• 23.1. North America Chikungunya Market Overview
• 23.2. North America Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chikungunya Market

• 24.1. USA Chikungunya Market Overview
• 24.2. USA Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chikungunya Market

• 25.1. Canada Chikungunya Market Overview
• 25.2. Canada Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chikungunya Market

• 26.1. South America Chikungunya Market Overview
• 26.2. South America Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chikungunya Market

• 27.1. Brazil Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chikungunya Market

• 28.1. Middle East Chikungunya Market Overview
• 28.2. Middle East Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chikungunya Market

• 29.1. Africa Chikungunya Market Overview
• 29.2. Africa Chikungunya Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chikungunya Market, Segmentation By Product Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chikungunya Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chikungunya Market Competitive Landscape And Company Profiles

• 30.1. Chikungunya Market Competitive Landscape
• 30.2. Chikungunya Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

31. Chikungunya Market Other Major And Innovative Companies

• 31.1. Eurofins Scientific SE
• 31.2. Grifols Diagnostic Solutions Inc.
• 31.3. bioMerieux SA
• 31.4. Bio-Rad Laboratories Inc.
• 31.5. DiaSorin S.p.A.
• 31.6. Euroimmun AG
• 31.7. Evotec SE
• 31.8. Valneva SE
• 31.9. ELITechGroup S.A.S.
• 31.10. Vaxart Inc.
• 31.11. BioPerfectus Biotechnology Co. Ltd.
• 31.12. CTK Biotech Inc.
• 31.13. Creative Diagnostics Inc.
• 31.14. Inovio Pharmaceuticals Inc.
• 31.15. Biotrol Laboratories Pvt. Ltd.

32. Global Chikungunya Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chikungunya Market

34. Recent Developments In The Chikungunya Market

35. Chikungunya Market High Potential Countries, Segments and Strategies

• 35.1 Chikungunya Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chikungunya Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chikungunya Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer